CLINICAL UTILITY OF THE SERUM CA-19-9 TEST FOR DIAGNOSING PANCREATIC-CARCINOMA IN SYMPTOMATIC PATIENTS - A PROSPECTIVE-STUDY

被引：35

作者：

MALESCI, A

MONTORSI, M

MARIANI, A

SANTAMBROGIO, R

BONATO, C

BISSI, O

TACCONI, M

WIZEMANN, G

SPINA, G

机构：

[1] Istituto di Medicina Interna, Universita’ di Milano, Milan

[2] Istituto di Semeiotica Chirurgica, Universita’ di Milano, Milan

[3] Istituto di Clinica Chirurgica I, Universita’ di Milano, Milan

来源：

PANCREAS | 1992年 / 7卷 / 04期

关键词：

CA-19-9; PANCREATIC CARCINOMA; PANCREATIC IMAGING TECHNIQUES; PROSPECTIVE STUDY;

D O I：

10.1097/00006676-199207000-00012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The diagnostic accuracy of the serum CA 19-9 determination was prospectively evaluated in patients selected for the presence of signs or symptoms highly suggestive for pancreatic cancer. Of 110 patients included in the study, 54 had a final diagnosis of pancreatic adenocarcinoma (49% prevalence). CA 19-9 values were higher than 40 U/ml in 45 patients with pancreatic carcinoma and in 18 of the 56 patients with other final diagnosis (sensitivity, 0.83; specificity, 0.68; positive predictive value [PPV], 0.71; negative predictive value [NPV], 0.81). The serum CA 19-9 determination was not capable of shortening the diagnostic workup of patients with strong clinical suspicion of pancreatic cancer since adequate imaging of the pancreas was required to confirm or exclude the diagnosis. However, values above 120 U/ml were strongly suggestive for pancreatic carcinoma in the overall population (PPV, 0.85) and they were diagnostic (PPV, 1.0) in the anicteric portion. Combined with pancreatic imaging, the CA 19-9 was an excellent confirmatory test; a normal value in a patient with negative imaging ruled out pancreatic carcinoma as the cause of symptoms (NPV, 1.0), whereas a pathological result in the presence of positive or equivocal pancreatic radiology was highly suggestive for the presence of the disease (PPV, 0.93).

引用

页码：497 / 502

页数：6

共 13 条

[1]

Ritts R.E., Del Villano B.C., Go V., Herberman R.B., Klug T.L., Zurawski V.R., Initial clinical evaluation of an immuno-radiometric assay using NCI serum bank, Int J Cancer, 33, pp. 339-345, (1984)

[2]

Malesci A., Tommasini M., Bocchia P., Et al., Differential diagnosis of pancreatic cancer and chronic pancreatitis by a monoclonal antibody detecting a new cancer associated antigen (CA 19-9), Ric Clin Lab, 14, pp. 303-306, (1984)

[3]

Tatsuta M., Yamamura H., Iishi H., Et al., Values of CA 19-9 in the serum, pure pancreatic juice and aspirated pancreatic material in diagnosis of malignant pancreatic tumor, Cancer, 56, pp. 2669-2673, (1985)

[4]

Schmiegel W.H., Kreiker C., Eberl W., Et al., Monoclonal antibody defines CA 19-9 in pancreatic juices and sera, Gut, 26, pp. 456-460, (1985)

[5]

Steinberg W.M., Gelfand R., Erson K.K., Et al., Comparison of the sensitivity and specificity of the CA 19-9 carcinoem-bryonic assays in detecting cancer of the pancreas, Gastroenterology, 90, pp. 343-349, (1986)

[6]

Malesci A., Tommasini M.A., Bonato C., Et al., Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis, Gastroenterology, 92, pp. 60-67, (1987)

[7]

Frebourg T., Bercoff E., Mancohn N., Et al., The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer, Cancer, 62, pp. 2287-2290, (1988)

[8]

Richter J.M., Christensen M.R., Rustgi A.K., Silverstein M.D., The clinical utility of the CA 19-9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss, Arch Intern Med, 149, pp. 2292-2297, (1989)

[9]

Pleskow D.K., Berger H.J., Gyves J., Allen E., McLean A., Pod-Olsky D., Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer, Ann Intern Med, 110, pp. 704-709, (1989)

[10]

Moosa A.R., Levin B., The diagnosis of “early” pancreatic cancer: The University of Chicago experience, Cancer, 47, pp. 1688-1697, (1981)

← 1 2 →